Almoosa Health Company (TADAWUL:4018)
Saudi Arabia · Delayed Price · Currency is SAR 116.20
-1.50 (-1.27%)
Aug 13, 2026, 3:16 PM AST
Almoosa Health Company Income Statement
Financials in millions SAR. Fiscal year is January - December.
Millions SAR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,498 | 1,416 | 1,202 | 978.97 | 816.04 | 701.54 | |
Revenue Growth | 14.15% | 17.79% | 22.82% | 19.97% | 16.32% | 11.54% |
Cost of Revenue | 1,057 | 993.19 | 834.02 | 674.5 | 587.73 | 486.9 |
Gross Profit | 441.69 | 423.1 | 368.32 | 304.47 | 228.31 | 214.64 |
Selling, General & Admin | 248.01 | 219.11 | 200.05 | 190.33 | 172.75 | 147.89 |
Other Operating Expenses | -25.2 | -22.49 | -18.22 | -13.82 | - | - |
Operating Expenses | 237.61 | 203.46 | 186.23 | 180.44 | 172.75 | 147.89 |
Operating Income | 204.08 | 219.64 | 182.09 | 124.03 | 55.56 | 66.75 |
Interest Expense | -15.82 | -18.15 | -80.53 | -22.59 | -15.38 | -3.82 |
Interest & Investment Income | 5.35 | 8.64 | - | - | - | - |
Earnings From Equity Investments | 0.86 | 0.54 | 1.19 | - | - | - |
Other Non Operating Income (Expenses) | -24.78 | 29.84 | -45.07 | - | 15.36 | 9.03 |
EBT Excluding Unusual Items | 169.7 | 240.5 | 57.67 | 101.45 | 55.54 | 71.96 |
Gain (Loss) on Sale of Assets | 0.21 | 0.22 | 0.11 | 0.33 | 0.03 | -0.07 |
Asset Writedown | - | - | - | - | -0.01 | -0.01 |
Pretax Income | 172.64 | 240.72 | 57.78 | 101.78 | 55.56 | 71.88 |
Income Tax Expense | 9.24 | 4.17 | 8.43 | 3.63 | 4.54 | 9.46 |
Net Income | 163.4 | 236.54 | 49.35 | 98.15 | 51.02 | 62.42 |
Net Income to Common | 163.4 | 236.54 | 49.35 | 98.15 | 51.02 | 62.42 |
Net Income Growth | -5.04% | 379.28% | -49.71% | 92.38% | -18.27% | -40.42% |
Shares Outstanding (Basic) | 44 | 44 | 35 | 35 | 35 | 0 |
Shares Outstanding (Diluted) | 44 | 44 | 35 | 35 | 35 | 0 |
Shares Change | 12.17% | 26.15% | - | - | 34900.00% | - |
EPS (Basic) | 3.69 | 5.36 | 1.41 | 2.80 | 1.46 | 624.20 |
EPS (Diluted) | 3.69 | 5.36 | 1.41 | 2.80 | 1.46 | 624.20 |
EPS Growth | -15.35% | 279.95% | -49.71% | 92.38% | -99.77% | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -582.06 | -284.27 | -56.66 | -343.12 | -318.15 | -120.76 |
Free Cash Flow Per Share | -13.14 | -6.44 | -1.62 | -9.80 | -9.09 | -1207.55 |
Dividend Per Share | 1.200 | 1.300 | 1.000 | - | - | - |
Dividend Growth | -25.00% | 30.00% | - | - | - | - |
Gross Margin | 29.48% | 29.87% | 30.63% | 31.10% | 27.98% | 30.59% |
Operating Margin | 13.62% | 15.51% | 15.14% | 12.67% | 6.81% | 9.52% |
Profit Margin | 10.91% | 16.70% | 4.11% | 10.03% | 6.25% | 8.90% |
Free Cash Flow Margin | -38.85% | -20.07% | -4.71% | -35.05% | -38.99% | -17.21% |
EBITDA | 295.77 | 305.01 | 257.04 | 182.72 | 105.45 | 88.99 |
EBITDA Margin | 19.74% | 21.54% | 21.38% | 18.67% | 12.92% | 12.68% |
D&A For EBITDA | 91.69 | 85.37 | 74.95 | 58.69 | 49.89 | 22.24 |
EBIT | 204.08 | 219.64 | 182.09 | 124.03 | 55.56 | 66.75 |
EBIT Margin | 13.62% | 15.51% | 15.14% | 12.67% | 6.81% | 9.52% |
Effective Tax Rate | 5.35% | 1.73% | 14.59% | 3.57% | 8.17% | 13.16% |
Advertising Expenses | - | 24.51 | 19.17 | 8.96 | 10.58 | 7.2 |